Avida Biomed are an early startup who have developed a novel targeted methylation sequencing technology: Point-n-Seq, for cancer early-detection. Point-n-Seq uses targeted methylation sequencing, which performs enrichment of target molecules directly from cfDNA before bisulfite conversion and amplification. Target panels are small 1-1000 markers. The […]
Mammoth Biosciences, one of the two companies developing CRISPR as a diagnostic tool, submitted a medRxiv preprint showcasing their work on a Covid-19 assay. The SARS-CoV-2 DETECTR assay generate results in 30 minutes from from extracted patient sample RNA. The assay performs simultaneous reverse transcription […]
The announcement of the first $100 30x human genome (reagents only) from Rade Drmanac in the final slot at #AGBT20 means that@MGI_BGI’s DNBSeq Tx is going to be the biggest sequencer in the world. However. it remains to be seen if the $100 genome will be an […]
In Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection researchers at the Institute of Human Genetics in Austria demonstrate the use of cfDNA for cancer detection and monitoring. The group performed deep ATAC-Seq and deep cfDNA nucleosome mapping to […]
Illumina’s response to the CMA’s recent findings that their acquisition of PacBio would be anti-competitive was published on the CMA website today. And both theirs, and PacBio’s stock are up (a little bit) as a result. Their suggested remedies include: To grant a perpetual, royalty-free, […]
October 25th was my birthday so I’ve been on holiday and waited till I got back before writing this post. There’s been lots of other coverage e.g. GenomeWeb, Motley Fool. Keith at OmicsOmics included a bit more on the other NGS players and emerging technologies and is worth […]
Yesterday Illumina and Qiagen announced a 15 year deal to partner on development of NGS in vitro diagnostic kits to run on Illumina sequencers. And Qiagen, more quietly, announced that development of the GeneReader platform will cease. The second piece of news is unsurprising; I’d written about Qiagens […]
The UK’s Industrial Strategy program just announced a £250 million program for early detection of disease. A public:private partnership with £79 million for the UK Govt plus £160 million from businesses and charities will be used to fund the Accelerating Detection of Disease programme. This […]
The current CMA report “Anticipated acquisition by Illumina, Inc. of Pacific Biosciences of California, Inc. Decision on relevant merger situation and substantial lessening of competition” makes for some interesting, if frustrating, reading. Interesting because of what the report says but frustrating because of the redaction […]
